1. Home
  2. TXMD vs LPTX Comparison

TXMD vs LPTX Comparison

Compare TXMD & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TXMD
  • LPTX
  • Stock Information
  • Founded
  • TXMD 2008
  • LPTX 2011
  • Country
  • TXMD United States
  • LPTX United States
  • Employees
  • TXMD N/A
  • LPTX N/A
  • Industry
  • TXMD Biotechnology: Pharmaceutical Preparations
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TXMD Health Care
  • LPTX Health Care
  • Exchange
  • TXMD Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • TXMD 12.7M
  • LPTX 11.1M
  • IPO Year
  • TXMD N/A
  • LPTX N/A
  • Fundamental
  • Price
  • TXMD $1.07
  • LPTX $0.28
  • Analyst Decision
  • TXMD
  • LPTX Hold
  • Analyst Count
  • TXMD 0
  • LPTX 1
  • Target Price
  • TXMD N/A
  • LPTX N/A
  • AVG Volume (30 Days)
  • TXMD 17.2K
  • LPTX 2.0M
  • Earning Date
  • TXMD 08-12-2025
  • LPTX 08-14-2025
  • Dividend Yield
  • TXMD N/A
  • LPTX N/A
  • EPS Growth
  • TXMD N/A
  • LPTX N/A
  • EPS
  • TXMD N/A
  • LPTX N/A
  • Revenue
  • TXMD $2,559,000.00
  • LPTX N/A
  • Revenue This Year
  • TXMD $427.09
  • LPTX N/A
  • Revenue Next Year
  • TXMD N/A
  • LPTX N/A
  • P/E Ratio
  • TXMD N/A
  • LPTX N/A
  • Revenue Growth
  • TXMD 156.93
  • LPTX N/A
  • 52 Week Low
  • TXMD $0.70
  • LPTX $0.22
  • 52 Week High
  • TXMD $2.44
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • TXMD 42.48
  • LPTX 44.35
  • Support Level
  • TXMD $1.05
  • LPTX $0.27
  • Resistance Level
  • TXMD $1.12
  • LPTX $0.31
  • Average True Range (ATR)
  • TXMD 0.04
  • LPTX 0.02
  • MACD
  • TXMD -0.00
  • LPTX 0.00
  • Stochastic Oscillator
  • TXMD 15.46
  • LPTX 38.33

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Share on Social Networks: